Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

Update: 2024-05-07

Description

Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

2024-07-3118:23

Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy

2024-07-0125:05

Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS

2024-05-1723:16

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

2024-05-0719:55

Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa

2024-04-2220:54

Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake

2024-03-1216:39

Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity

2024-03-0123:19

Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region

2023-12-1914:40

Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy

2023-11-2914:45

Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease

2023-10-1216:19

Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction

2023-09-1316:31

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

2023-08-1014:29

Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease

2023-07-1217:41

Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis

2023-06-0712:48

Adelina Artenie on the incidence of HIV and HCV in people who inject drugs

2023-05-1017:15

Johan Burisch on the costs of inflammatory bowel disease in high-income settings

2023-04-1220:00

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

2023-02-0821:30

Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer

2023-01-2320:20

Dan Turner on vedolizumab in children with IBD

2023-01-0614:51

Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection

2022-11-0915:21

00:00

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

#box-pro-ellipsis-172746572079373{-webkit-line-clamp:2;}Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

The Lancet Group

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease